Coeptis Therapeutics, Inc. (COEP)
NASDAQ: COEP · IEX Real-Time Price · USD
0.291
+0.009 (3.26%)
At close: Jul 11, 2024, 4:00 PM
0.299
+0.008 (2.68%)
After-hours: Jul 11, 2024, 7:23 PM EDT

Coeptis Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019
Revenue
000.080.030
Revenue Growth (YoY)
--143.82%--
Cost of Revenue
0000.960
Gross Profit
000.08-0.930
Selling, General & Admin
14.8234.1814.125.780
Research & Development
6.670.02000
Operating Expenses
21.4934.214.125.780
Operating Income
-21.49-34.2-14.05-6.71-0
Interest Expense / Income
0.110.220.190.150
Other Expense / Income
-0.333.16-0.782.29-
Pretax Income
-21.27-37.57-13.45-9.16-0
Net Income
-21.27-37.57-13.45-9.16-0
Shares Outstanding (Basic)
261411182
Shares Outstanding (Diluted)
261411182
Shares Change
79.70%30.98%-39.66%944.93%-
EPS (Basic)
-0.83-2.63-1.23-0.51-
EPS (Diluted)
-0.83-2.63-1.23-0.51-
Free Cash Flow
-7.24-3.88-4.49-3.14-0
Free Cash Flow Per Share
-0.28-0.27-0.41-0.17-0.00
Gross Margin
--100.00%-3034.54%-
Operating Margin
---18727.91%-21823.77%-
Profit Margin
---17932.37%-29765.89%-
Free Cash Flow Margin
---5985.92%-10195.12%-
EBITDA
-20.16-36.35-12.81-8.68-0
EBITDA Margin
---17086.31%-28232.72%-
Depreciation & Amortization
110.450.320
EBIT
-21.16-37.36-13.26-9.01-0
EBIT Margin
---17682.86%-29284.14%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).